- Home
- NUVL vs HESM Comparison
NUVL vs HESM Comparison
Compare NUVL & HESM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUVL
- HESM
- Stock Information
- Founded
- NUVL 2017
- HESM 2014
- Country
- NUVL United States
- HESM United States
- Employees
- NUVL N/A
- HESM N/A
- Industry
- NUVL Biotechnology: Pharmaceutical Preparations
- HESM Oil & Gas Production
- Sector
- NUVL Health Care
- HESM Energy
- Exchange
- NUVL Nasdaq
- HESM Nasdaq
- Market Cap
- NUVL 5.8B
- HESM 5.6B
- IPO Year
- NUVL 2021
- HESM N/A
- Fundamental
- Price
- NUVL $77.76
- HESM $42.52
- Analyst Decision
- NUVL Strong Buy
- HESM Buy
- Analyst Count
- NUVL 10
- HESM 5
- Target Price
- NUVL $119.60
- HESM $46.40
- AVG Volume (30 Days)
- NUVL 482.8K
- HESM 1.8M
- Earning Date
- NUVL 08-11-2025
- HESM 07-30-2025
- Dividend Yield
- NUVL N/A
- HESM 6.93%
- EPS Growth
- NUVL N/A
- HESM 17.37
- EPS
- NUVL N/A
- HESM 2.69
- Revenue
- NUVL N/A
- HESM $1,570,600,000.00
- Revenue This Year
- NUVL N/A
- HESM $13.01
- Revenue Next Year
- NUVL N/A
- HESM $11.48
- P/E Ratio
- NUVL N/A
- HESM $15.82
- Revenue Growth
- NUVL N/A
- HESM 9.02
- 52 Week Low
- NUVL $55.54
- HESM $33.59
- 52 Week High
- NUVL $113.51
- HESM $44.14
- Technical
- Relative Strength Index (RSI)
- NUVL 43.20
- HESM 65.43
- Support Level
- NUVL $77.41
- HESM $39.82
- Resistance Level
- NUVL $83.50
- HESM $44.14
- Average True Range (ATR)
- NUVL 3.08
- HESM 1.22
- MACD
- NUVL -0.75
- HESM 0.42
- Stochastic Oscillator
- NUVL 14.84
- HESM 74.25
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
About HESM Hess Midstream LP Share
Hess Midstream LP owns, operates, develops, and acquires a diverse set of midstream assets and provides fee-based services to Hess and third-party customers. It conducts its business through three operating segments: gathering, processing and storage, and terminaling and exporting. The company derives the maximum revenue from the gathering segment. Its gathering segment consists of the following assets namely Natural Gas Gathering and Compression; Crude Oil Gathering and Produced Water Gathering and Disposal.